Last reviewed · How we verify
KX2-391 and Paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
KX2-391 and Paclitaxel (KX2-391 and Paclitaxel) — Hanmi Pharmaceutical Company Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KX2-391 and Paclitaxel TARGET | KX2-391 and Paclitaxel | Hanmi Pharmaceutical Company Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- KX2-391 and Paclitaxel CI watch — RSS
- KX2-391 and Paclitaxel CI watch — Atom
- KX2-391 and Paclitaxel CI watch — JSON
- KX2-391 and Paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). KX2-391 and Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/kx2-391-and-paclitaxel. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab